Introduction
Pediatric hematopoietic stem cell transplantation (HSCT), in particular allogeneic HSCT, is associated with a large spectrum of neurologic complications that significantly contribute to patients' morbidity and mortality. The most frequent neurologic complications are CNS infections, cerebrovascular or metabolic events, and neurotoxicity of immunosuppressive agents manifesting as posterior reversible encephalopathy syndrome (PRES).
HSCT). Transplant features of our population, including type of HSCT, source of stem cells, donors, conditioning, anti-graft versus host disease (anti-GvHD) prophylaxis, cytomegalovirus reactivation and neurological complications are detailed in Table 1 .
We used computerized EEG and Cell Therapy Unit databases to retrospectively identify patients aged 0-18 years with a definite diagnosis of epileptic seizures within a year from HSCT. We excluded patients with paroxysmal events of non-epileptic origin. We collected information regarding patient's age, sex, underlying disease, transplant features (type of HSCT, source of stem cells, donors, conditioning, anti-GvHD prophylaxis), characteristics of seizures (etiology, time from HSCT procedure, semiology, duration, ictal and post ictal EEGs, neuroimaging) and outcome.
An antiepileptic prophylaxis with valproic acid was given to all patients treated with busulphan (BU) as conditioning regimen.
Etiology of seizures was classified as follows:
Transplant related etiologies PRES associated with calcineurin inhibitors neurotoxicity. PRES was defined as a clinical-radiological entity characterized by encephalopathy, headache, seizures and visual disturbances with a typical imaging pattern showing cortical and subcortical potentially reversible vasogenic edema, most commonly affecting the posterior regions of the brain. 10 Dimethylsulfoxide (DMSO) and/or BU neurotoxicity. Metabolic disturbances. CNS infections. Cerebrovascular disorders. Encephalopathy of unknown etiology.
Non-transplant related etiologies Symptomatic epilepsy secondary to CNS involvement of underlying disorder. Seizures in patients with previously diagnosed epilepsy were considered in the study and classified as non-transplant related neurological complications of HSCT.
Semiology of seizures was classified in accordance with ILAE classification.
11
Status epilepticus (SE) was defined as 30 min of continuous seizure activity or a series of seizures without return to full consciousness between seizures.
12 Non-convulsive SE (NCSE) was defined as impaired consciousness for more than 30 min, with some epileptic electrographic seizure activity without overt convulsions but with a plethora of different cognitive, behavioral, and minor motor features. 13 Seizure activity during NCSE was defined according to Kaplan EEG criteria. 14 In the case of a seizure, the following investigations were performed: whole blood count, glycemia, electrolytes, C-reactive protein, blood gas analysis, transaminases, urea, creatinine. Blood pressure was tested at least daily in all patients. Lumbar puncture was performed in the case of suspected viral or bacterial CNS infection.
Our EEG practice is to perform a bedside recording early on after the occurrence of neurological signs or symptoms or at the onset of consciousness alteration. Standard EEG tracings are obtained for at least 30 min. If the first EEG recording shows abnormalities, serial EEGs are repeated on the following days. If seizure activity or SE is detected, a prompt pharmacological treatment is provided and EEG is continued to monitor the effects of therapy. EEG studies were reviewed by a pediatric neurologist experienced in pediatric EEG.
Neuroimaging was obtained in all children with suspected neurological complications. Computerized tomography (CT) scans of the brain were performed as soon as possible in the case of focal neurological signs or prolonged consciousness alteration, to exclude cerebrovascular disorders. Magnetic resonance imaging (MRI) techniques included FSE and fluid attenuated inversion recovery (FLAIR), T2WI, diffusion weighted images (DWI), T1WI, and MR angiography 3D TOF. Neuroimages were reviewed by a pediatric neuroradiologist.
Statistical methods
Patients were divided into those with seizures and those without seizures.
To determine the risk factors for seizures in HSCT children each variable was initially analyzed with a univariate model using Cox regression. Variables with p < 0.05, according to univariate analyses, were entered in a Cox regression model for multivariate analysis.
Survival rates were estimated using the Kaplan-Meier method using the GraphPad Prism version 6.0 software. 
Results
Thirty-eight neurological complications after HSCT were observed in 37 of the 261 patients (14.2%) who underwent HSCT in our Unit from January 2000 to December 2010.
A total of 61 seizures were observed in 28 patients; in 24, seizures were a manifestation of transplant related neurological complications; the remaining four patients had a previous diagnosis of epilepsy secondary to CNS disease before HSCT. Ten of the 28 patients with seizures have been described in a previous paper. 9 Patient features, with clinical and transplant data are described in Table 1 .
Etiology of seizures
Seizure features are described in Table 2 . PRES was the etiology of seizures in 14 patients (associated with CsA in 13 cases and with FK506 in 1 case); CNS infections in 4 patients (S. aureus meningoencephalitis, Aspergillus encephalitis, brain abscess, Epstein Barr Virus-post-transplant lymphoproliferative disorders [EBV-PTLD]); DMSO, BU and metabolic disturbance (hypomagnesaemia) in 1 patient; in 4 patients seizures occurred during an encephalopathy of unknown origin. One patient was considered twice because she presented with seizures as a manifestation of PRES and three months later she relapsed with seizures secondary to CNS infection. The remaining four patients had a previous diagnosis of epilepsy secondary to CNS disease before HSCT.
Timing of seizure presentation
Patients developed seizures following HSCT after a median period of 78 days (range À3; +352), in case of PRES it was 65 days (range 5-352). See Fig. 1 for details.
Seizures were the presentation of underlying neurological complications in 22 patients. In particular 11 out of 14 patients with PRES presented with seizures.
Frequency and semiology of seizures
Sixteen patients had a single seizure. 12 patients had repeated seizures (range: 2-8 seizures). In 10 out of these 12 patients, seizures recurred within the first week after onset. In the other 2 patients, both with PRES, an isolated and apparently unprovoked seizure occurred 50 and 76 days respectively after the first seizure.
In most patients the onset of the first seizure was characterized by non-convulsive focal signs such as gaze deviation, oculoclonic movements, visual hallucinations sometimes associated with altered mental status. Non-convulsive clinical features were observed at onset of seizure in 20 patients and in particular in 12 cases of PRES. In detail, in 9/28 patients seizures onset was characterized by gaze deviation, 7 of them had PRES; in 5/28 patients, seizures developed with gaze deviation associated with impairment of consciousness, 3 had PRES. In 2 cases of PRES seizures started respectively with oculoclonic movements and visual hallucinations; seizures started with impairment of consciousness in 4/28 patients. Evolution to a bilateral, convulsive seizure was signaled in 10 patients. The onset of seizures was characterized by motor involvement in 8 patients: generalized tonic-clonic seizures in 5/28 patients and emiclonic seizures in 3/28.
Status epilepticus
16 episodes of SE in 14 patients were identified: 10 convulsive SE and 6 NCSE. Median duration of SE was 175 min (range 40-1000 min). EEG monitoring was used in patients with NCSE during the ictal and early post-ictal phases to assess the efficacy of therapeutic intervention. 12 patients with SE had a diagnosis of PRES and 2 presented two SE.
Ictal and postictal EEG
Ictal EEGs were obtained in 9 patients; in 6 of them etiology was PRES, in 2 symptomatic epilepsy secondary to CNS involvement of underlying disorder, in 1 encephalopathy of unknown etiology. In all cases of PRES ictal EEG showed rhythmic spikes involving unilateral or bilateral parieto-occipital or temporal-occipital regions. All patients were closely followed-up by repeated EEG in the early post-ictal period. At least one EEG was obtained for all patients in the first 48 h after first seizure: in all cases it was characterized by focal or generalized slow electrical activity; in patients with PRES slowing was more evident on posterior regions of the brain. PLEDs associated with slow activity were recorded in 5 patients, all with PRES.
Treatment
Longer or repeated seizures were stopped in all but one patient with the use of antiepileptic drugs (AEDs); in all patients we used as first line treatment benzodiazepines (diazepam and/or midazolam): 16 patients required repeated administrations of benzodiazepines and/or administration of phenytoin i.v. Only one patient with refractory SE needed the use of an anesthetic agent (propofol). 12/28 patients needed intensive care unit (ICU) admission to support vital functions; 10 of them had PRES.
The causes of the seizures were treated: electrolytic imbalance was corrected, in patients with PRES the ongoing calcineurin inhibitor treatment was stopped and subsequently replaced by a different immunosuppressant agent and in patients with CNS infection specific treatment with antibiotic or anti-fungal or antiviral drugs was administered based on the underlying disease.
All patients were treated with AEDs during the acute phase and in 11 cases a prophylaxis with AEDs was continued after the resolution of the neurological complication for a median time of 2 months (range 2 weeks-18 months).
Neuroimaging
Neuroimaging studies were performed in 26 patients. Early CT scans were performed in 12 patients with focal neurological signs or prolonged consciousness alteration. MRI was performed in the first 72 h after seizure in 21 patients. In 2 patients brain imaging was not obtained: in one patient because of the critical clinical conditions; the other had previously diagnosed epilepsy. In the cases of PRES brain imaging was characterized by a posteriorpredominant pattern of cortical-subcortical involvement: focal lesions confined to parietal and/or occipital lobes and more extensive multifocal or diffuse lesions which involved frontal and temporal lobes, cerebellum and basal ganglia were observed. In one patient we observed an acute PRES-related intraparenchymal hemorrhage in the left temporal lobe. No correlation was observed between the duration of seizures and the extension of brain involvement.
In patients with CNS infections MRI imaging showed: a focal lesion with perilesional edema in the case of EBV-PTLD; an abscess lesion; diffuse edema in a patient with S. Aureus encephalitis; mycetomas in the case of Aspergillus infection. Cerebral imaging was negative in patients with a diagnosis of electrolyte disturbance, DMSO and BU toxicity, in 2 patients with encephalopathy of unknown etiology and in one patient with seizures due to underlying disease (meningeal leukemia). In the cases of CNS malignancies MRI showed the tumor lesion or the surgical lesion if the tumor was removed.
Risk factors
Univariate analysis in the whole population recognized the following possible risk factors for seizures: a diagnosis of nononcological disease, allogeneic HSCT, cord blood stem cell (CBSC) transplantation and BU-based conditioning regimen. Multivariate analysis identified as independent risk factors for seizures (in the whole population and in allo-HSCT population) a diagnosis of nononcological disease and CBSC transplantation. See details in Table 3 .
Outcome
By December 2010 17/28 patients had died. They died after a mean period of 9 months from HSCT due to complications linked to the underlying disease or to other HSCT complications. Two patients died because of neurological complications: one due to fungal infection, the other due to EBV-PTLD with cerebral localization. Overall survival for patients with seizures was 32.3% over 5 years compared to 45.8% in patients without seizures (p < 0.05) (see Fig. 2 ). Patients with SE had a poorer prognosis: 11/14 died against 6/14 patients without SE. No patients developed epilepsy during the follow-up period.
Discussion
Our data show that seizures are a frequent manifestation of neurological complications after pediatric HSCT. In most cases seizures were the first manifestation of underlying neurological complications; moreover, they were often repeated and/or long lasting requiring intensive treatment. These data emphasize the importance of timely diagnosis and treatment of seizures and their causes. This study is the first attempt to investigate clinical and EEG features and analyze etiologies of epileptic seizures after pediatric HSCT.
In the present study seizures occurred in 10.7% of all patients and in 73.6% of patients with neurological complications after HSCT; in the literature seizures are reported in 6.9-11.7% of transplanted patients and in about 52.6-75.0% of patients with neurological complications.
1,4-8 The high incidence of seizures in our population may be partially explained by the different populations and definitions of neurological complications used in the studies. However, we suggest that our practice of the routine use of EEG monitoring may have improved the detection of non-convulsive seizures and NCSE in our population. In fact, we observed at onset of seizures non-convulsive clinical features in 20/28 patients. In our experience the use of EEG monitoring at the occurrence of neurological signs or symptoms is a useful and practical approach to diagnose promptly and treat mildly symptomatic seizures or NCSE in children after HSCT. Moreover the data of the present study confirm that long lasting non-convulsive seizures beginning with subtle and stereotyped clinical signs such as gaze deviation, oculoclonic movements and mental status changes associated with a particular localization of EEG ictal and/or postictal abnormalities (rhythmic epileptiform activity, PLEDs and/or slowing) in the posterior regions of the brain are particularly suggestive of PRES, as we have already described in a recent paper. 9 The recognition of this pattern will enable clinicians to suspect PRES also before neuroradiological confirmation. PRES occurred exclusively in allo-HSCT patients and was the main etiology of seizures in our population. PRES related to cyclosporine or FK506 has been recognized as a major cause of seizures after HSCT.
2,4,15 PRES was a cause of early seizures, occurring in the first 100 days after HSCT in all patients but one. Interestingly, in our study all 14 patients with PRES had seizures, and in 11 of them seizures were the first manifestation, underlining the particular epileptogenicity of this encephalopathy. 16, 17 Seizures due to DMSO and or BU neurotoxicity, metabolic disturbances and CNS infections showed in our patients less distinctive electroclinical features than PRES. However, other characteristics such as timing, clinical features, laboratory or neuroradiological examinations were useful in our experience to suggest and confirm etiological diagnosis. Very early seizures occurring suddenly during conditioning in a previously neurologically intact patient were usually secondary to DMSO or BU neurotoxicity 3, 18, 19 ; in the case of metabolic disturbance diagnosis was easily obtained by laboratory examinations. Seizures in the setting of CNS infections were associated with other suggestive laboratory data and/or clinical signs such as fever and were rarely the first manifestation of the neurological complication. Neuroimaging, and in particular MRI, was confirmed as a fundamental tool to obtain a correct diagnosis in neurological complications after HSCT. According to literature data, MRI was normal in cases of DMSO and BU toxicity and in metabolic disturbances and showed very typical and specific findings in PRES and in CNS bacterial and mycotic infections. 20 Although in our experience we observed only one patient with PRES-related cerebral hemorrhage, we strongly suggest the use of early neuroimaging (CT and/or MRI) in patients with focal neurological signs to exclude cerebral bleeding. A rapid clinical evaluation at the occurrence of neurological signs and symptoms, including early neuroimaging, EEG monitoring and laboratory tests are mandatory for a correct etiological diagnosis of seizures in HSCT setting. SE, often but not always secondary to PRES, was observed in half of our patients. SE was recently described as the main manifestation of PRES after pediatric HSCT. 9 SE is a potential life-threatening event and can lead to neurologic sequelae such as secondary epilepsy, cognitive deterioration, behavioral problems and focal neurologic deficits. 21 Our data show that SE occurring after HSCT is usually not easy to treat and may require intensive care management to support vital functions. The risk factors for seizures after pediatric HSCT identified by multivariate statistical analysis in our population (diagnosis of non-oncological disease and CBSC transplantation) differ from those recently described by other authors in adult patients. 8 This fact may be explained by the diversity of transplant procedures and population characteristics between pediatric and adult HSCT patients. Other factors that were suspected to increase the risk of seizures in transplanted children, such as BU-based conditioning regimen and allogeneic transplantation, were associated with seizures in univariate analysis but were not statistically significant in multivariated analysis. In our experience a very high mortality rate was observed in children presenting seizures after HSCT. A similar mortality rate has been described in adult patients with seizures after allo-HSCT. 8 In interpreting these data we have to take into account that severe neurological complications have been described as a possible cause of increased morbidity and mortality after pediatric allo-HSCT. 1, 2 Moreover, long lasting seizures are known to be related to a poor outcome in critically ill patients 22 and our results confirm that SE is associated with a poor prognosis in transplanted children. On this basis, we strongly suggest that a prompt and aggressive acute antiepileptic treatment should be ensured in patients with seizures after HSCT. Data are lacking in the literature about how long to continue AEDs therapy after occasional seizures associated with neurological complications. Some authors suggested continuing the antiepileptic therapy on a long term basis in pediatric patients with PRES. 23 However, considering the occasional/provoked nature of the seizures, in most of our patients prophylactic treatment with AEDs (benzodiazepines and/or phenytoin) was usually used only during the acute phase of the neurological complication. Moreover, no patients with seizures secondary to neurological complications of HSCT developed epilepsy during the follow-up. We suggest that prolonged prophylactic treatment with AEDs is not needed in patients with occasional/provoked seizures after HSCT and it should be considered in the event of a later development of secondary epilepsy.
Conclusions
This study shows that seizures are a frequent and severe event after pediatric HSCT. PRES was the main etiology of seizures in our population. Seizures secondary to PRES showed a particular and recognizable electroclinical pattern, recognition of which may make clinicians suspect PRES also before neuroradiological confirmation. In our experience the early use of EEG monitoring in addition to careful clinical, laboratory tests and neuroimaging work-up is required in patients with seizures after HSCT to diagnose and treat correctly seizures and their causes. Finally, we suggest that, although a prompt and aggressive acute antiepileptic treatment has to be ensured, a long lasting prophylactic therapy with AEDs is not usually necessary in these patients.
